Latest Headlines

Latest Headlines

Sun enjoys fleeting profit boost from oxaliplatin

Talk about a rollercoaster: Sun Pharma profits tripled in the first quarter, driven by one-time U.S. sales of chemotherapy drug oxaliplatin. But, alas, the generics maker stopped manufacturing the

Genzyme manufacturing woes yield patent threat

Of the many financial ramifications of drug manufacturing negligence--plant and process retooling, FDA fines, product and inventory seizure, consultant fees, shareholder and consumer suits, brand

China: See, we're trying!

Last year, China ranked third among the 20 countries filing patents for aseptic applications. Its 21 submissions in 2008 tower over its 2003 accomplishment of just one. "This clearly demonstrates